BioMarin looks for fast approval of hemophilia A gene therapy; Investigators tout Entasis antibiotic

BioMarin $BMRN told analysts during its R&D day that new FDA rules may make it possible to file for an FDA approval on its hemophilia A gene therapy valrox, if the Phase I/II study continues as expected.

→ Investigators involved in a Phase II study of a new antibiotic say that a single oral dose worked in treating gonorrhea. Zoliflodacin — developed by Entasis — works by inhibiting DNA biosynthesis.

→ The UK’s Vectura (LSE: $VEC) has inked a deal to work with Hikma on a generic version of GSK’s Ellipta. Vectura gets $15 million upfront with another $80 million in milestones.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,100+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->